Bionacre® Bone Graft
Bone defects and non-load bearing bone voids (Dental & Orthopedic Surgery)
ApprovedActive
Key Facts
Indication
Bone defects and non-load bearing bone voids (Dental & Orthopedic Surgery)
Phase
Approved
Status
Active
Company
About Mega Biopharma
Mega Biopharma is a private, clinical-stage biotech company pioneering a disruptive biomaterial platform based on nacre (mother-of-pearl). Its lead product, the Bionacre® Bone Graft, is positioned as a bioactive, fully resorbable graft for managing bone voids in dental and orthopedic applications, meeting key criteria for an ideal graft substitute. The company has achieved ISO 9001 certification and recently secured €7.5M in Pre-Series A funding, with a Series A round targeting €15M to propel growth. Mega Biopharma operates in the large and growing global bone graft substitute market, aiming to establish a new standard of care.
View full company profile